Alivus Life Sciences Ltd.

The March 2025 quarter revenue stood at Rs. 6495.45 millions, up 21.05% as compared to Rs. 5365.97 millions during the corresponding quarter last year.The company has announced a 44.86% increase in its profits to Rs . 1418.68  millions for the  quarter ended March 2025 compared to Rs. 979.37 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 2085.20 millions compared to 1445.77 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202503	202403	% Var	202503	202403	% Var	202503	202403	% Var
Sales	6495.45	5365.97	21.05	23868.84	22832.14	4.54	23868.84	22832.14	4.54
Other Income	100.88	31.31	222.20	345.70	120.42	187.08	345.70	120.42	187.08
PBIDT	2085.20	1445.77	44.23	7171.54	6862.88	4.50	7171.54	6862.88	4.50
Interest	12.60	3.64	246.15	24.14	15.46	56.14	24.14	15.46	56.14
PBDT	2072.60	1442.13	43.72	7147.40	6847.42	4.38	7147.40	6847.42	4.38
Depreciation	159.70	145.34	9.88	606.09	534.52	13.39	606.09	534.52	13.39
PBT	1912.90	1296.79	47.51	6541.31	6312.90	3.62	6541.31	6312.90	3.62
TAX	494.22	317.42	55.70	1685.04	1604.02	5.05	1685.04	1604.02	5.05
Deferred Tax	15.45	6.88	124.56	60.64	81.88	-25.94	60.64	81.88	-25.94
PAT	1418.68	979.37	44.86	4856.27	4708.88	3.13	4856.27	4708.88	3.13
Equity	245.07	245.05	0.01	245.07	245.05	0.01	245.07	245.05	0.01
PBIDTM(%)	32.10	26.94	19.15	30.05	30.06	-0.04	30.05	30.06	-0.04